Dr Jessica Baker Flechtner, Chief Scientific Officer, Genocea Biosciences, Inc.
17:40 3/30/2016 "Panel: The future combination cancer immunotherapies with vaccines, checkpoint inhibitors and oncolytic viruses"
11:30 3/31/2016 "Smarter identification of T cell antigens from infectious disease to cancer"
Dr Seth Hetherington, Chief Medical Officer, Genocea Biosciences
17:10 3/30/2016 "Positive top-line Phase II data for genital herpes immunotherapy"
Dr George Siber, CSO of ClearPath Vaccines & Scientific Advisory Board of Genocea, ClearPath Vaccines
9:00 3/30/2016 "Chair’s opening remarks"
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM